Market Closed -
Other stock markets
|
|
5-day change | 1st Jan Change | |
30.52 USD | -0.03% | -4.98% | +9.19% |
Nov. 27 | Wells Fargo Adjusts Price Target on Omega Healthcare Investors to $33 From $34, Maintains Equal-Weight Rating | MT |
Nov. 07 | North American Morning Briefing : Higher Bond -2- | DJ |
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- This company will be of major interest to investors in search of a high dividend stock.
- Analyst opinion has improved significantly over the past four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- The firm trades with high earnings multiples: 27.56 times its 2023 earnings per share.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector : Specialized REITs
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+9.19% | 7 477 M $ | B | ||
+33.82% | 48 550 M $ | A- | ||
+3.71% | 18 786 M $ | A- | ||
-25.21% | 10 258 M $ | A | ||
-18.47% | 6 048 M $ | B- | ||
+13.76% | 3 269 M $ | C+ | ||
-18.14% | 3 172 M $ | B+ | ||
-13.13% | 2 993 M $ | B+ | ||
-57.90% | 2 807 M $ | C | ||
-17.20% | 2 738 M $ | A- |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock
- Equities
- Stock Omega Healthcare Investors, Inc. - Nyse
- Ratings Omega Healthcare Investors, Inc.